Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The interferon-gamma (IFN-γ) releasing assay (IGRA) is widely used for latent tuberculosis infection (LTBI) diagnosis.
|
31432637 |
2020 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Five enrollment strategies were assessed: 1) Enroll based on no LTBI diagnostic test, 2) Enroll based on a positive tuberculin skin test (TST), 3) Enroll based on a positive interferon gamma release assay (IGRA), 4) Enroll based on either a positive TST or IGRA, 5) Enroll regardless of test result, assuming 70% had negative TSTs, 20% positive TSTs, and 10% unknown results.
|
31711306 |
2020 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of these, 37 (32%) presented LTBI - tuberculin skin test was positive in 18 (49%) patients; interferon gamma release test was positive in 14 (38%) patients and undetermined in seven (19%); and there was a history of exposure in 12 (32%) patients.
|
31206406 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The laboratory diagnosis of latent tuberculosis infection (LTBI) is mainly performed with interferon gamma release assays (IGRAs).
|
31533984 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interferon gamma release assay (IGRA) was used for the diagnosis of LTBI.
|
31561559 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>Mycobacterium tuberculosis</i>-Induced Bronchoalveolar Lavage Gene Expression Signature in Latent Tuberculosis Infection Is Dominated by Pleiotropic Effects of CD4<sup>+</sup> T Cell-Dependent IFN-γ Production despite the Presence of Polyfunctional T Cells within the Airways.
|
31541022 |
2019 |
Latent Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conducted a cross-sectional analysis of baseline data from a UK cohort study which enrolled participants at risk of latent tuberculosis infection (LTBI, defined as a positive result for either of the two interferon gamma release assays).
|
29764958 |
2019 |
Latent Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Estimating the annual risk of tuberculosis infection in Japan from interferon-gamma release assay data.
|
30315813 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Good Agreement between an Interferon Gamma Release Assay and Tuberculin Skin Tests in Testing for Latent Tuberculosis Infection among HIV-Infected Patients in Indonesia.
|
31625291 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The overall initiation rate of LTBI treatment was suboptimal in HCWs with LTBI diagnosed using an interferon-gamma releasing assay.
|
30635600 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interferon-gamma release assays (IGRAs) are blood tests used to measure the amount of interferon-γ (IFN-γ) released by T lymphocytes after stimulation by antigens specific for the diagnosis of latent tuberculosis infection.
|
31132974 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current guidelines recommend screening for latent tuberculosis infection (LTBI) with a tuberculin skin test (TST) or interferon gamma release assay (IGRA), or both.
|
31363778 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of interferon gamma release assays for detection of latent tuberculosis is discussed and compared to tuberculin skin testing.
|
30817030 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The tuberculin skin test (TST) and interferon-gamma-release-assays (IGRAs) are utilized in screening programmes for presumed latent tuberculosis infection (LTBI) in health care workers (HCWs).
|
30736743 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnosis of LTBI relies on presence of immune-reactivity to TB antigen and commonly used tests include tuberculin skin test and interferon gamma release assay (IGRA).
|
30741387 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current tests measure an immunologic response and include the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs), T-SPOT.TB and QuantiFERON.
|
31731987 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given the lack of a gold standard for latent tuberculosis infection (LTBI) and paucity of performance data from endemic settings, we compared test performance of the tuberculin skin test (TST) and two interferon-gamma-release assays (IGRAs) among health-care workers (HCWs) using latent class analysis.
|
31416206 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A strategy is described for continuous monitoring of multiple latent tuberculosis infection (LTBI) biomarkers, specifically of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α) and interleukin-2 (IL-2).
|
30830301 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When compared to gold standard technology (interferon gamma release assay or IGRA), our encapsulated immunoassay accurately predicted LTBI diagnosis in 11 out of 14 patients.
|
30776214 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil.
|
30673986 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnostic accuracy of interferon-gamma-induced protein 10 for differentiating active tuberculosis from latent tuberculosis: A meta-analysis.
|
31388072 |
2019 |
Latent Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we found that <i>IFNG</i> and <i>IFNGR1</i> polymorphisms were associated with LTBI.
|
31687049 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Incidence and risk factors of latent tuberculosis tests conversion (interferon gamma release assays [IGRA], tuberculin skin tests [TST], and chest radiography [CXR]) with clinical outcomes were studied.
|
29757355 |
2018 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of tuberculin skin test and interferon gamma release assay for diagnosis of latent tuberculosis infection in pediatric candidates of renal transplantation.
|
29388291 |
2018 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
At our institution, CXR was performed for all patients undergoing a tuberculin skin test (TST) and/or an interferon-gamma release assay (IGRA) at the LTBI screening visit.
|
30261981 |
2018 |